The Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg is coordinating an EU project for research into new active compounds against Parkinson’s disease (PD). SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease) is the name of the project that just started with the involvement of five universities and three companies from Luxembourg, Germany, Ireland, the Netherlands and UK. The European Union is funding the researchers of this consortium with a total of 5.9 million euros.
With this funding, they will be developing novel techniques by which to identify and research into active compounds against PD. They will furthermore be advancing drug candidates towards their medical application.
“Universities and biopharmaceutical companies complement each other’s expertise ideally in SysMedPD,” says Prof. Rudi Balling, LCSB director and coordinator of SysMedPD. “This creates optimal conditions in which to progress a good deal further in developing diagnoses and therapies for Parkinson’s disease.”
Parkinson’s disease is a gradually progressive disease of human nerve tissue, resulting among other things in muscle tremors and muscle rigidity. The mitochondria of nerve cells are often causally involved in the onset – mitochondria being the power plants of cells, in which biochemical reactions provide energy for cellular metabolic processes.
“We estimate that in about ten to twenty percent of all Parkinson’s patients, their mitochondria do not function properly,” says senior LCSB scientist Dr Ronan Fleming, who is significantly involved in the conception and coordination of SysMedPD. “In order to better diagnose, heal or at least effectively curb the progression of Parkinson’s disease, we must understand this dysfunction of mitochondria in detail.”
The researchers within SysMedPD are first concentrating on such patterns of PD in which the mitochondria are damaged by mutations in individual genes. “Later, the results can then be carried over to patient groups in which multiple genes and environmental factors are involved in the onset of PD,” adds Dr Fleming.
The SysMedPD consortium will tackle this task with different approaches: “At the LCSB, we place emphasis on developing new, computational models by which we can better depict the processes going on inside mitochondria,” Ronan Fleming says. Prof. Jens Schwamborn, head of the LCSB group Development and Cell Biology, describes a complementary approach: “We must verify any computational predictions using experiments. Therefore, in the scope of this EU project, we will also employ advanced cellular models, where skin samples obtained from Parkinson’s disease patients are reprogrammed into living human nerve cells.”
To ensure the research results obtained within SysMedPD are translated into application as quickly as possible, the consortium also has biopharmaceutical companies on board. Their areas of involvement are test development for new active compounds and identification of active compounds.
“The project is organised such that the insights that we and the other academic partners gain will complement those of the companies involved very well,” says Prof. Rudi Balling. “With this close connection between public and private research, we can ensure the EU funding, firstly, is employed optimally in the interest of the PD patients and, secondly, will generate economic stimuli. These are important objectives of the EU that we will fulfil here.”
The SysMedPD partners:
- Germany: University of Lübeck (Prof. Christine Klein), EURICE – European Research and Project Office GmbH (Corinna Hahn)
- Ireland: Maynooth University (Dr Niall Finnerty)
- Luxembourg: University of Luxembourg (Prof. Rudi Balling, Dr Ronan Fleming, Prof. Jens Schwamborn)
- Netherlands: Leiden University (Prof. Thomas Hankemeier), Khondrion BV (Prof. Jan Smeitink), Mimetas BV (Dr Paul Vulto)
- Great Britain: University College London (Prof. Anthony Schapira)
http://www.uni.lu/lcsb - Homepage of the Luxembourg Centre for Systems Biomedicine
Britta Schlüter | Universität Luxemburg - Université du Luxembourg
'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton
A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.
Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
19.09.2017 | Event News
19.09.2017 | Physics and Astronomy
19.09.2017 | Power and Electrical Engineering